Search tips
Search criteria 


Logo of procrsmedFormerly medchtJournal of the Royal Society of MedicineProceedings of the Royal Society of Medicine
Proc R Soc Med. 1975 April; 68(4): 211–216.
PMCID: PMC1863786

New experimental and clinical data on leukaemia immunotherapy.


The present results of our treatment of acute lymphoid leukaemia patients are summarized: 7 out of 20 randomized patients given active immunotherapy after chemoradiotherapy are still in complete remission after periods varying from seven to ten years (compared to none in the control group). The actuarial results on 100 patients show remission and survival curves presenting a plateau between three and five years for a certain percentage, suggesting a possible cure. Several parameters studied in 200 patients indicate that the factors affecting this percentage are age, cytological type, volume of the tumour, and the localization of leukaemic cells in certain areas. Experiments with L1210 leukaemia show that immunotherapy enhances the effect of chemotherapy when administered after chemotherapy but decreases it when administered before, which is in favour of the use of the sequence chemotherapy-immunotherapy clinically.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Amiel JL, Berardet M. An experimental model of active immunotherapy preceded by cytoreductive chemotherapy. Eur J Cancer. 1970 Dec;6(6):557–559. [PubMed]
  • BIOZZI G, STIFFEL C, HALPERN BN, MOUTON D. [Effect of inoculation with Calmette-Guerin bacillus on the development of Ehrlich ascites tumor in the mouse]. C R Seances Soc Biol Fil. 1959;153:987–989. [PubMed]
  • Gutterman JU, Mavligit G, McBride C, Frei E, 3rd, Freireich EJ, Hersh EM. Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet. 1973 Jun 2;1(7814):1208–1212. [PubMed]
  • Mathe G, Amiel JL, Pouillart P, Schwarzenberg L, Hayat M, de Vassal F, Belpomme D, Lafleur M. L'espérance de guérison des enfants atteints de leucémie aiguë lymphoïde. Les facteurs du pronostic au début de la maladie et leur valeur en tant qu'indications thérapeutiques. Arch Fr Pediatr. 1974 Feb-Mar;31(2):271–283. [PubMed]
  • Mathé G, Amiel JL, Schwarzenberg L, Schneider M, Cattan A, Schlumberger JR, Hayat M, De Vassal F. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969 Apr 5;1(7597):697–699. [PubMed]
  • Mathé G, Pouillart P, Lapeyraque F. Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer. 1969 Dec;23(4):814–824. [PMC free article] [PubMed]
  • Mathé G, Pouillart P, Schwarzenberg L, Amiel JL, Schneider M, Hayat M, De Vassal F, Jasmin C, Rosenfeld C, Weiner R, et al. Attempts at immunotherapy of 100 patients with acute lymphoid leukemia: some factors influencing results. Natl Cancer Inst Monogr. 1972 Dec;35:361–372. [PubMed]
  • Mathe G, Pouillart P, Sterescu M, Amiel JL, Schwarzenberg L, Schneider M, Hayat M, de Vassal F, Jasmin C, Lafleur M. Subdivision of classical varieties of acute leukemia. Correlation with prognosis and cure expectancy. Rev Eur Etud Clin Biol. 1971 Jun-Jul;16(6):554–560. [PubMed]
  • OLD LJ, CLARKE DA, BENACERRAF B. Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature. 1959 Jul 25;184(Suppl 5):291–292. [PubMed]
  • Pouillart P, Schwarzenberg L, Schneider M, Amiel JL, Mathé G. Les méningites lymphoblastiques. Incidence, prévention et traitement. Nouv Presse Med. 1972 Feb 5;1(6):387–390. [PubMed]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press